Formulation development and in-vitro evaluation of montelukast sodium pressurized metered dose inhaler

Volume: 56, Pages: 101534 - 101534
Published: Apr 1, 2020
Abstract
Montelukast is used as alternative treatment for asthma. However, some adverse drug reactions have been reported for the oral dosage form of montelukast. To counter this issue, the drug was formulated into a pressurized metered-dose inhaler (pMDI), which delivered montelukast directly to the lower regions of the lungs. Montelukast sodium, mixed with either HFA 134a propellant or a mixed propellant (HFA-134a and HFA227), was formulated into a...
Paper Details
Title
Formulation development and in-vitro evaluation of montelukast sodium pressurized metered dose inhaler
Published Date
Apr 1, 2020
Volume
56
Pages
101534 - 101534
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.